Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

NCT03016819 is registered in ClinicalTrials.gov with Advenchen Laboratories, LLC as lead sponsor.

NCT NCT03016819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03016819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Lead sponsor
Advenchen Laboratories, LLC
Phase
Phase 3
Overall status
Recruiting
Start date
August 15, 2017
Completion date
December 31, 2028
Enrollment
325 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar soft part sarcoma, leiomyosarcoma, soft-tissue sarcoma, synovial sarcoma